NEA leads $38.9 mln Series B funding in Intact Vascular

New Enterprise Associates led a $38.9 million Series B funding round in Intact Vascular, Inc., which develops medical devices for minimally invasive vascular procedures. Other participants in the funding included Quaker Partners, H.I.G. BioVentures and other existing investors. NEA Partner Justin Klein joined Intact Vascular’s board. Press Release Intact Vascular, Inc., a developer of medical […]

NEA leads Series D round for Cartiva

Alpharetta, Georgia-based Cartiva Inc, a provider of solutions for patients with osteoarthritis or cartilage damage, has raised $8.5 million in Series D funding. New Enterprise Associates led the round with participation from Windham Ventures Partners.


Robinhood scores $50 mln in NEA-led round

Retail brokerage platform Robinhood has raised $50 million in funding, the company announced in a blog post on its site. New Enterprise Associates led the round with participation from Index Ventures, Ribbit Capital, Social Leverage and Vaizra Investments. In addition to the funding, Kittu Kolluri of NEA has been added to Robinhood’s board of directors.

Moximed picks up about $33 mln

Hayward, California-based Moximed, a maker of solutions for patients with knee osteoarthritis, has secured about $33 million in funding. The investors included Vertex Venture Holdings Ltd, New Enterprise Associates, Gilde Healthcare Partners, Morgenthaler Ventures and GBS Venture Partners. In addition to the funding, Dr. Christopher Shen of Vertex, has been added to Moximed’s board of directors.

NVCA appoints True Ventures’ Callaghan as chairman

The National Venture Capital Association has named Jon Callaghan chairman of its board of directors. A founder and general partner of True Ventures, Callaghan is succeeding Scott Sandell, general partner of New Enterprise Associates. In addition to this appointment, ten new board members were announced at NVCA’s annual meeting held in San Francisco. Among them are Mike Carusi, general partner of Lightstone Ventures; Jeff Clavier, founder and managing director of SoftTech VC; Michael Dixon, a partner at Sequoia Capital; and Mary Meeker, a partner at Kleiner Perkins Caufield & Byers.


CRISPR Therapeutics raises $64 mln

CRISPR Therapeutics said Wednesday it raised $64 million in financing, including $35 million in a Series A and $29 million in a Series B. Strategic investors, SR One and Celgene Corp., led the rounds while new investors New Enterprise Associates and Abingworth, alongside the Company’s founding investor, Versant Ventures, also participated. CRISPR Therapeutics, of Basel, Switzerland, is a biopharmaceutical company.


Xplore closes buy of VC-backed Motion Computing

Xplore Technologies Corp. has completed its previously announced acquisition of substantially all of the assets of Austin, Texas-based Motion Computing Inc, a maker of rugged tablet PCs. The value of the transaction is about $9 million, which includes $7 million in net liabilities. Motion Computing’s backers included New Enterprise Associates, Institutional Venture Partners and G-51 Capital.


Hello Alfred collects $10.5 mln Series A

Boston and New York City-based subscription errand service Hello Alfred has raised $10.5 million in Series A funding. New Enterprise Associates and Spark Capital led the round with participation from Sherpa Ventures and CrunchFund.


VC-backed Engine Yard acquires OpDemand

Engine Yard has bought OpDemand, a maker of Deis, an open source application platform for Docker. No financial terms were disclosed. Engine Yard is backed by Benchmark, New Enterprise Associates, Oracle and Amazon.


Pocket picks up $7 mln in NEA-led round

San Francisco-based Pocket, a platform that helps users save online content, has closed $7 million in funding. New Enterprise Associates led the round with participation from other investors that included Axel Springer, Digital Garage and Ashton Kutcher and Guy Oseary’s new fund Sound Ventures. In conjunction with the funding, Dayna Grayson, a general partner at NEA, has been added to Pocket’s board of directors.

VC-backed Blend Therapeutics appoints Fromkin as president and CEO

Watertown, Massachusetts-based Blend Therapeutics Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has named Drew Fromkin as president, CEO and a member of the company’s board of directors. Previously, Fromkin worked at Clinical Data Inc where he served as President and CEO. Blend Therapeutics’ backers include Eminent Venture Capital, Flagship Ventures, NanoDimension and New Enterprise Associates.


Niara grabs $20 million in Venrock-led round

Sunnyvale, California-based Niara, a stealth security startup, has raised $20 million in Series B funding. Venrock led the round with participation from other investors that included New Enterprise Associates and Index Ventures. In conjunction with the funding, Doug Dooley of Venrock has been appointed to Niara’s board of directors.


Folloze picks up $3.3 mln seed

Palo Alto, California-based Folloze, a B2B prospect engagement platform, has raised $3.3 million in seed funding. New Enterprise Associates, TriplePoint Capital and Cervin Ventures led the round.


3D imaging company Fyusion raises $13 mln

3D imaging company Fyusion has raised $13 million in a Series B round led by New Enterprise Associates and The University of Tokyo Edge Capital. Undisclosed angel investors also participated. The San Francisco-based company, which provides the Fyuse app for processing 3D images, last year raised $3.35 million in a Series A round.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget